Journal: Diabetology & metabolic syndrome
Article Title: Insulin lispro low mixture twice daily vs basal insulin glargine once daily and prandial insulin lispro once daily as insulin intensification strategies in patients with type 2 diabetes: Latin American subpopulation analysis of a randomized trial.
PMID/MRN: 27660663
Publication Date: 2016-12-06
Abstract:
This post hoc analysis examined the efficacy and safety of twice-daily insulin lispro low mixture (LM25) and once-daily basal insulin glargine plus once-daily prandial insulin lispro (IGL) in a Latin American subpopulation with type 2 diabetes mellitus (T2DM).
A phase 4, randomized, open-label, parallel-arm trial included participants aged 18-75Êyears with T2DM taking once-daily insulin glargine and stable doses of metformin and/or pioglitazone with glycated hemoglobin (HbA1c) 7.5-10.5Ê% and fasting plasma glucoseʲ121Êmg/dL. Participants were randomized 1:1 to receive their stable dose of metformin and/or pioglitazone plus twice-daily LM25 or IGL for 24Êweeks. The primary efficacy outcome was change in HbA1c after 24Êweeks of treatment. Results from participants in Argentina, Brazil, and Mexico are presented here.
162 participants (80 LM25; 82 IGL) with meanʱÊstandard deviation (SD) ageÊ=Ê57.3ʱÊ9.0Êyears and body mass indexÊ=Ê31.3ʱÊ5.2Êkg/m(2) were included. MeanʱÊSD change in HbA1c from baseline to week 24 was -1.5ʱÊ1.0Ê% (LM25) and -1.1ʱÊ1.2Ê% (IGL). At week 24, 35.1Ê% (LM25) and 31.6Ê% (IGL) of participants achieved HbA1cÊ<7.0Ê%. MeanʱÊSD weight gain from baseline to week 24 was 2.4ʱÊ2.9Êkg in the LM25 group and 1.0ʱÊ3.1Êkg in the IGL group. The meanʱÊSD rates of total hypoglycemia per year were 18.9ʱÊ27.3 (LM25) and 21.6ʱÊ31.1Ê(IGL). Rates of treatment-emergent adverse events were 46Ê% (LM25) and 39Ê% (IGL).
Our results suggest that both LM25 and IGL are viable treatment options for insulin intensification in Latin American patients with T2DM with suboptimal glycemic control on basal insulin glargine. The safety and tolerability profiles of LM25 and IGL are consistent between this Latin American population and the global trial-level population. Trial registration NCT01175824.